Meijer, Ruben P. J.
Galema, Hidde A.
Faber, Robin A.
Bijlstra, Okker D.
Maat, Alexander P. W. M.
Cailler, Françoise
Braun, Jerry
Keereweer, Stijn
Hilling, Denise E.
Burggraaf, Jacobus
Vahrmeijer, Alexander L.
Hutteman, Merlijn
,
Warmerdam, Mats I.
Azari, Feredun
Singhal, Sunil
Almandawi, Dima D. A.
Mahtab, Edris A. F.
Shahin, Ghada M. M.
Doukas, Michail
Verhoef, Cornelis
Framery, Bérénice
Article History
Received: 21 April 2023
Accepted: 24 July 2023
First Online: 8 August 2023
Declarations
:
: This study was reviewed and approved by the medical ethical committee ‘Leiden-Den Haag-Delft’ on February 11, 2020 (ERB reference number: P19.101).
: Written informed consent was obtained from all individual participants included in this study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figs. , , , and and supplemental Fig. .
: FC and BF are employed by SurgiMab and are co-inventors of the patent that protects SGM-101. FC is also a co-founder of SurgiMab. All other authors declare no conflict of interest.